ADC

192개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved192 programs
ADCLimited DatastaleSun Yat-sen UniversityPhase 3

Anti-PD1 combined with Becotatug Vedotin (Anti-PD1 combined with Becotatug Vedotin)

Nasopharyngeal Cancinoma (NPC) · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#ADC#Phase3#antibody-drug-conjugate#Sun
Trials 1Status Recruiting
ADCLimited DatastaleCentral South UniversityPreclinical

Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate (Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate)

Sepsis (SMQ); Opportunistic Infections · Sepsis (SMQ)

#SepsisSMQ#ADC#Preclinical#antibody-drug-conjugate#OpportunisticInfections+1
Trials 1Status Active
ADCLimited DatastaleFudan UniversityPhase 2

B2: TROP2 ADC with Camrelizumab (B2: TROP2 ADC with Camrelizumab)

Triple-negative Breast Cancer · TROP2

#TROP2#ADC#Phase2#antibody-drug-conjugate#Triple-negativeBreastCancer+1
Trials 1Status Recruiting
ADCLimited DatastaleWest China Second University Ho…Phase 2

MRG003 (Becotatug Vedotin, Becotatug Vedotin (MRG003))

Gastric Cancer; Gastroesophageal Junction (GEJ) Adenocarcinoma · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#GastroesophagealJunctionGEJAdeno+1
Trials 1Status Recruiting
ADCLimited DatastaleWest China HospitalPhase 2

Becotatug Vedotin Combined with Ivonescimab (Becotatug Vedotin Combined with Ivonescimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#West
Trials 1Status Recruiting
ADCLimited DatastaleFeng LiuPhase 2

Becotatug Vedotin Combined with PD-1 Inhibitor (Becotatug Vedotin Combined with PD-1 Inhibitor)

Head and Neck Squamous Cell Carcinoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleWest China HospitalPhase 2

Becotatug Vedotin Combined with Penpulimab (Becotatug Vedotin Combined with Penpulimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#West
Trials 1Status Recruiting
ADCLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Becotatug Vedotin combined with Pucotenlimab (Becotatug Vedotin combined with Pucotenlimab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#ADC#Phase2#antibody-drug-conjugate#Shanghai
Trials 1Status Recruiting
ADCLimited DatastaleShanghai Ninth People's Hospita…Phase 2

sacituzumab govitecan (Trodelvy, Becotatug Vedotin or Sacituzumab Tirumotecan)

Adenoid Cystic Carcinoma of the Head and Neck; SBRT · Adenoid Cystic Carcinoma of the Head and

#AdenoidCysticCarcinomaoftheHeada#ADC#Phase2#antibody-drug-conjugate#SBRT+1
Trials 1Status Recruiting
ADCLimited DatastaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages)

AL Amyloidosis; Amyloidosis · AL Amyloidosis

#ALAmyloidosis#ADC#Phase2#antibody-drug-conjugate#Amyloidosis+1
Trials 1Status Recruiting
ADCLimited DatastaleAmgenPhase 2

Blinatumomab and Inotuzumab Ozogamicin (Blinatumomab and Inotuzumab Ozogamicin)

Acute Lymphoblastic Leukemia; Immunotherapy · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#ADC#Phase2#antibody-drug-conjugate#Immunotherapy+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPreclinical

brentuximab vedotin (Adcetris, Brentuximab Vedotin Plus CHP)

CD30-Positive Peripheral T-Cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30-PositivePeripheralT-CellLym+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPhase 1

brentuximab vedotin (Adcetris, Brentuximab vedotin and rifampicin)

Hodgkin Lymphoma; Anaplastic Large-cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase1#antibody-drug-conjugate#AnaplasticLarge-cellLymphoma+1
Trials 1Status Active
ADCLimited DatastaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#antibody-drug-conjugate#RelapsedorRefractoryHodgkinLymph+1
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin + tislelizumab + bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Fruquintinib)

HER2; Colorectal Cancer · HER2

#HER2#ADC#Approved#antibody-drug-conjugate#ColorectalCancer+1
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MuscleInvasiveBladderCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Radiotherapy)

HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-expressingHigh-riskorVeryHi+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Zimberelizumab)

Biliary Carcinoma · Biliary Carcinoma

#BiliaryCarcinoma#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 1Status Active

7 / 10 pages

← PreviousNext →